Double maintains 2 strategies that include DNTH - Dianthus Therapeutics, Inc.
Yahoo
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Yahoo
Dianthus Therapeutics ( NASDAQ:DNTH ) Full Year 2024 Results Key Financial Results Net loss: US$85.0m (loss widened by...
Yahoo
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H’26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H’26 $357.0 million of cash provides runway into 2H’27 NEW YORK and WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- D
Yahoo
Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion Mr. King also led the commercial strategy behind the first FDA-approved, self-administered, subcutaneous biologic for gMG as the Chief Commercial Officer of Ra Pharma, acquired by UCB for $2.5 billion Mr. Kango has >26 years of industry experience spanning senior executive, commercial and business developmen
Yahoo
NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at the following investor conferences: TD Cowen 45th Annual Health Care Conference – Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Wednesday, March 5 at 11:50 a.
Yahoo
NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February: Guggenheim SMID Cap Biotech Conference – Fireside chat
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AXS | -0.01% | $8.17B | +54.61% | 1.78% |
TAC | -0.04% | $2.85B | +50.95% | 1.86% |
WTRG | 0.06% | $10.85B | +9.33% | 3.12% |
RYAN | 0.06% | $9.44B | +43.71% | 0.59% |
PARAA | -0.06% | $15.13B | +2.22% | 0.89% |
FOX | 0.07% | $24.03B | +84.60% | 1.08% |
TTE | 0.08% | $135.10B | -10.80% | 5.37% |
SPNT | -0.10% | $2.88B | +39.50% | 0.00% |
GEO | 0.13% | $4.21B | +109.82% | 0.00% |
BBVA | -0.13% | $79.67B | +16.11% | 5.27% |
TW | -0.14% | $31.68B | +48.00% | 0.28% |
SO | -0.14% | $100.14B | +28.63% | 3.09% |
UUU | -0.15% | $4.14M | +11.18% | 0.00% |
MKTX | -0.16% | $7.95B | -1.91% | 1.34% |
HURN | 0.18% | $2.61B | +53.94% | 0.00% |
PBH | 0.21% | $4.26B | +23.91% | 0.00% |
PNW | 0.21% | $11.38B | +30.58% | 3.68% |
ERIE | 0.23% | $19.35B | +4.10% | 1.25% |
DOGZ | 0.24% | $372.37M | +260.22% | 0.00% |
WRB | 0.25% | $26.45B | +22.49% | 0.51% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TRVG | -15.65% | $104.93M | +63.70% | 0.00% |
VHC | -13.90% | $35.77M | +37.68% | 0.00% |
HEES | -13.81% | $3.51B | +50.35% | 1.17% |
SCM | -11.60% | - | - | 11.70% |
PRT | -11.09% | $49.92M | -3.00% | 11.26% |
CME | -10.51% | $94.61B | +23.82% | 3.89% |
PM | -10.26% | $242.82B | +71.62% | 3.29% |
SEG | -9.74% | $269.93M | -17.45% | 0.00% |
KDP | -8.89% | $47.68B | +13.32% | 2.55% |
CBOE | -8.87% | $23.50B | +25.53% | 1.05% |
CLX | -8.35% | $18.19B | +0.54% | 3.24% |
AFL | -8.28% | $61.28B | +31.80% | 1.86% |
AFG | -8.09% | $11.10B | +3.74% | 2.32% |
AEP | -7.99% | $57.54B | +27.77% | 3.31% |
LNT | -7.99% | $16.55B | +30.41% | 2.98% |
MASI | -7.57% | $9.27B | +21.93% | 0.00% |
KO | -7.27% | $306.97B | +19.22% | 2.66% |
CMS | -7.26% | $22.33B | +25.86% | 2.76% |
BNED | -7.17% | $364.72M | -83.00% | 0.00% |
STNG | -7.02% | $1.87B | -48.89% | 4.57% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -22.89% | $416.76M | 1.43% |
VIXY | -17.94% | $195.31M | 0.85% |
UUP | -16.14% | $325.79M | 0.77% |
USDU | -14.81% | $206.96M | 0.5% |
TAIL | -13.71% | $87.65M | 0.59% |
CTA | -9.23% | $978.30M | 0.76% |
JMST | -8.18% | $3.54B | 0.18% |
ULST | -8.09% | $585.14M | 0.2% |
CCOR | -6.14% | $64.12M | 1.18% |
ICLO | -5.40% | $354.74M | 0.2% |
UGA | -4.04% | $87.23M | 0.97% |
FLRN | -3.46% | $2.84B | 0.15% |
UNG | -3.43% | $397.59M | 1.06% |
DBE | -3.34% | $55.52M | 0.77% |
FLTR | -3.34% | $2.41B | 0.14% |
IYK | -2.78% | $1.53B | 0.4% |
USL | -2.44% | $47.77M | 0.85% |
GBIL | -2.17% | $6.30B | 0.12% |
BNO | -2.13% | $99.25M | 1% |
CLOA | -2.07% | $783.46M | 0.2% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IMVT | 42.15% | $2.79B | -47.34% | 0.00% |
IMNM | 41.68% | $583.44M | -68.94% | 0.00% |
COGT | 40.06% | $651.22M | -16.98% | 0.00% |
ACLX | 39.14% | $3.69B | +6.38% | 0.00% |
SYRE | 39.02% | $933.38M | -55.31% | 0.00% |
RNA | 38.27% | $3.58B | +11.75% | 0.00% |
CRNX | 37.65% | $2.92B | -34.08% | 0.00% |
RCKT | 37.58% | $671.77M | -75.23% | 0.00% |
EYPT | 37.54% | $369.07M | -74.12% | 0.00% |
DNLI | 37.18% | $2.00B | -29.07% | 0.00% |
ELVN | 37.07% | $973.23M | +6.83% | 0.00% |
NTLA | 36.81% | $755.67M | -70.78% | 0.00% |
VSH | 36.73% | $2.16B | -28.21% | 2.94% |
IDYA | 36.47% | $1.43B | -61.21% | 0.00% |
AUTL | 35.90% | $417.82M | -71.40% | 0.00% |
ALEC | 35.82% | $116.92M | -79.97% | 0.00% |
BEAM | 35.72% | $1.85B | -37.74% | 0.00% |
SLAB | 35.65% | $3.79B | -13.44% | 0.00% |
APGE | 35.56% | $2.25B | -36.95% | 0.00% |
CRSP | 35.49% | $2.93B | -47.07% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 49.27% | $4.76B | 0.35% |
IBB | 46.67% | $5.61B | 0.45% |
GNOM | 44.48% | $47.13M | 0.5% |
RSPA | 42.02% | $292.67M | 0% |
ARKG | 40.35% | $936.86M | 0.75% |
PBE | 38.34% | $224.98M | 0.58% |
BBH | 38.17% | $358.88M | 0.35% |
IWC | 35.67% | $797.08M | 0.6% |
XRT | 35.63% | $363.44M | 0.35% |
PINK | 35.58% | $138.92M | 0.5% |
PTH | 34.06% | $107.91M | 0.6% |
QQA | 33.15% | $187.77M | 0% |
IWO | 33.10% | $10.72B | 0.24% |
BALT | 32.94% | $1.36B | 0.69% |
AOM | 32.63% | $1.45B | 0.15% |
XPH | 32.40% | $158.14M | 0.35% |
KJUL | 32.26% | $155.05M | 0.79% |
FBT | 32.09% | $1.08B | 0.56% |
IWM | 31.86% | $62.65B | 0.19% |
QQQJ | 31.80% | $592.09M | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DBA | -0.02% | $829.48M | 0.93% |
CORN | 0.03% | $52.17M | 0.2% |
MINT | 0.10% | $13.22B | 0.35% |
TPMN | 0.13% | $33.32M | 0.65% |
TBIL | -0.14% | $5.39B | 0.15% |
XLU | 0.18% | $18.06B | 0.09% |
SPSK | -0.20% | $300.65M | 0.5% |
VRIG | 0.30% | $1.44B | 0.3% |
KRBN | 0.33% | $175.08M | 0.85% |
IDU | 0.49% | $1.40B | 0.39% |
VPU | 0.55% | $6.83B | 0.09% |
KBA | 0.63% | $188.42M | 0.56% |
FUTY | 0.88% | $1.70B | 0.084% |
TFLO | -0.94% | $6.75B | 0.15% |
COMT | 0.94% | $684.20M | 0.48% |
OILK | -1.17% | $67.85M | 0.69% |
EQLS | 1.18% | $4.80M | 1% |
ASHR | -1.19% | $2.63B | 0.65% |
CLOI | 1.22% | $1.01B | 0.4% |
GSG | 1.24% | $1.05B | 0.75% |
Current Value
$16.611 Year Return
Current Value
$16.611 Year Return